Trisubstituted amine compound

1. A method for treatment of a disease involving CETP selected from the group consisting of arteriosclerosis, dyslipidemia, coronary artery disease, and hypertension, which comprises administering an effective amount of a compound of the general formula I-B):

wherein

Z A is N or CH;

A 21A is an optionally substituted homocyclic group, an optionally substituted alkylsulfanyl group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted alkyl group, a nitro group, a hydroxy group, a cyano group, an optionally substituted alkenyl group, an optionally substituted heterocyclic group, an optionally substituted alkoxy group, a halogen atom, an amino group optionally substituted by 1 to 2 substituents, a carbamoyl group optionally substituted by 1 to 2 substituents, a carboxyl group or a hydrogen atom;

R 1A is a cyano group or an alkyl group optionally substituted by 1 to 3 halogen atoms;

B′ is a group selected independently from an oxo group, a cyano group, a halogen atom, an optionally substituted alkylsulfanyl group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an amino group optionally substituted by 1 to 2 substituents, a hydroxy group, an optionally substituted heterocyclic group, an optionally substituted cycloalkoxy group, an optionally substituted cycloalkyl group, a carboxyl group, a carbamoyl group optionally substituted by 1 to 2 substituents, an optionally substituted alkyl group or an optionally substituted alkoxy group;

p A is an integer of 0 to 3;

D is a pyrimidinyl group, a pyridyl group, a phenyl group, a pyrimidinyloxy group, a tetrazolyl group or an oxazolidinyl group;

D′ is a group selected independently from a halogen atom, an alkoxyalkyl group, an alkyl group substituted by 1 to 5 halogen atoms, an alkoxy group substituted by 1 to 5 halogen atoms, an alkenyl group, a carbamoyl group, a cycloalkyl group, a mono- or di-alkylaminoalkyl group, a mono- or di-alkylaminoalkoxy group, a carboxyl group, a hydroxy group, a cyano group, an oxo group, an alkyl group, a hydroxyalkyl group, an alkoxycarbonylalkyl group, a carboxyalkyl group, a morpholinylalkyl group, a phenylalkyl group, an alkanoyl group, a hydroxyalkanoyl group, an alkoxyalkanoyl group, an alkoxy group, a phenylalkoxy group, an alkoxycarbonyl group, a benzyloxycarbonyl group, a mono- or di-alkylamino group, a mono- or di-alkylcarbamoyl group, a mono- or di-alkylsulfamoyl group, an alkylsulfonyl group, a tetrazolyl group, a benzyloxyalkyl group, a cycloalkylalkyl group, a benzyloxy group, an alkoxyalkoxy group, a carboxyalkoxy group, a carboxyalkenyl group, an alkylcarbonylamino group, a carboxyalkoxyalkyl group, a morpholinyl group or a pyridylalkoxy group;

q A is an integer of 0 to 3,

or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

2. The method of claim 1 , comprising administering a compound wherein

A 21A is selected from the following group:

(a) a heterocyclic group selected from a piperidyl group and a morpholinyl group, respectively optionally substituted by a substitutent(s) selected from a carboxyl group, an alkoxycarbonyl group, a carboxyalkyl group or an alkyl group;

(b) an alkoxy group optionally substituted by a group selected from a carboxyl group, an alkoxycarbonyl group, a halogen atom, an alkylsulfinyl group, a mono- or di-alkylamino group, a cyano group, a tetrazolyl group, an alkylsulfonyl group, an alkylsulfanyl group, a hydroxy group or an alkoxy group;

(c) a halogen atom;

(d) an amino group optionally substituted by 1 to 2 substituents independently selected from a carboxyalkyl group, an alkoxycarbonylalkyl group, an alkylsulfonylalkyl group, an alkylsulfinylalkyl group, a hydroxyalkyl group, an alkyl group, an alkoxyalkyl group or an aminoalkyl group optionally substituted by 1 to 2 alkyl groups;

(e) a hydrogen atom;

(f) an alkyl group optionally substituted by a group selected from a carboxyl group, an alkoxycarbonyl group, a halogen atom, an alkylsulfinyl group, a mono- or di-alkylamino group, a cyano group, a tetrazolyl group, an alkylsulfonyl group, an alkylsulfanyl group, a hydroxy group or an alkoxy group;

(g) a carboxyl group;

(h) a carbamoyl group optionally substituted by a carboxyalkyl group;

(i) an alkenyl group substituted by a group selected from a carboxyl group, an alkoxycarbonyl group, an alkylsulfinyl group, a cyano group, a tetrazolyl group, an alkylsulfonyl group, an alkylsulfanyl group, a hydroxy group or an alkoxy group;

(j) a morpholinyl group;

(k) a piperidinyl group optionally substituted by a carboxyl group or a carboxyalkyl group;

B′ is a group selected independently from an oxo group, a halogen atom, an alkyl group optionally substituted by 1 to 3 halogen atoms, an alkoxy group optionally substituted by 1 to 3 halogen atoms, a cyano group, a hydroxy group, a cycloalkyl group, an alkoxyalkyl group, a cycloalkoxy group, an alkylsulfanyl group optionally substituted by 1 to 3 halogen atoms, an alkylsulfinyl group optionally substituted by 1 to 3 halogen atoms or an alkylsulfonyl group optionally substituted by 1 to 3 halogen atoms;

or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , comprising administering a compound wherein

A 21A is an alkoxy group optionally substituted by 1 to 2 groups selected from a carboxyl group, a halogen atom, an alkoxycarbonyl group, an alkoxy group, a hydroxy group, a mono or di-alkylamino group, an alkylsulfinyl group, a cyano group, a tetrazolyl group, an alkylsulfonyl group and an alkylsulfanyl group; an alkyl group optionally substituted by 1 to 2 groups selected from a carboxyl group, a halogen atom, an alkoxycarbonyl group, an alkoxy group, a hydroxy group, a mono or di-alkylamino group, an alkylsulfinyl group, a cyano group, a tetrazolyl group, an alkylsulfonyl group and an alkylsulfanyl group; a morpholinyl group; a carboxyl group or a carboxypiperidinyl group;

B′ is a group selected independently from a halogen atom, an alkyl group optionally substituted by 1 to 3 halogen atoms or an alkoxy group optionally substituted by 1 to 3 halogen atoms;

D′ is a group selected independently from an alkoxy group optionally substituted by 1 to 3 halogen atoms, a halogen atom, a cyano group, an alkylsulfanyl group, a mono or di-alkylamino group, an alkenyl group, an alkyl group optionally substituted by 1 to 3 halogen atoms, a carboxyl group, a hydroxy group, a carboxyalkoxy group, a carboxyalkyl group, an alkoxycarbonylalkyl group, an oxo group, a cycloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carbamoyl group, a mono- or di-alkylcarbamoyl group, an alkylcarbonylamino group, a morpholinyl group or a carboxyalkoxyalkyl group, or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , comprising administering a compound wherein Z A is N, or a pharmaceutically acceptable salt thereof.

5. The method of claim 3 , comprising administering a compound wherein R 1A is an alkyl group optionally substituted by 1 to 3 halogen atoms, or a pharmaceutically acceptable salt thereof.

6. The method of claim 3 , comprising administering a compound wherein D is a phenyl group, or a pharmaceutically acceptable salt thereof.

7. The method of claim 3 , comprising administering a compound wherein D′ is a group selected independently from a halogen atom, an alkoxy group or an alkyl group, or a pharmaceutically acceptable salt thereof.

8. The method of claim 3 , comprising administering a compound wherein A 21A is a morpholinyl group or an alkoxy group substituted by a carboxyl group, or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , comprising administering a compound wherein:

A 21A is an alkoxy group substituted by a carboxyl group; or a carboxypiperidinyl group;

D is a pyridyl group, or a phenyl group;

D′ is a group selected independently from an alkoxy group; a halogen atom; an alkenyl group; an alkyl group optionally substituted by 1 to 3 halogen atoms; and a hydroxyalkyl group;

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , comprising administering a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , comprising administering a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

12. The method of claim 10 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the compound is the sodium salt of said compound.

14. The method of claim 10 , which is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 10 , wherein the compound is represented by the following chemical formula:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 10 , wherein the compound is represented by the following chemical formula:

or a pharmaceutically acceptable salt thereof.

17. The method of claim 1 , comprising administering a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 , wherein the disease involving CETP is arteriosclerosis.

19. The method of claim 18 , wherein the arteriosclerosis is atherosclerosis.

20. The method of claim 1 , wherein the disease involving CETP is dyslipidemia.

21. The method of claim 20 , wherein the dyslipidemia is hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypertriglyceridemia, or hypercholesterolemia.

22. The method of claim 1 , wherein the disease involving CETP is coronary artery disease.

23. The method of claim 1 , wherein the disease involving CETP is hypertension.

24. The method of claim 1 , wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of 0.01 to 100 mg/kg/day.